Table 2.
Technology Classification | Antigen Tests | Molecular Tests | ||||
---|---|---|---|---|---|---|
Test Classification | Near-POC | POC | Near-POC | Low-Complexity | ||
Developer, Product Name | LumiraDx, LumiraDx |
Pfizer, Lucira Health |
Visby, COVID-19 Test |
Biocartis, IdyllaTM |
||
Overall Score *,† | 73/110 (66%) | 83/110 (75%) | 78/110 (71%) | 66/110 (60%) | ||
Test summary | Platform: Specifications | Dimensions (cm) | 21 × 9.7 × 7.3 | 19.1 × 8.0 × 5.2 | 13.8 × 6.7 × 4.4 | 30.5 × 19 × 50.5 |
Weight (g) | 1100 | 150 | NR | 18,600 | ||
Power-supply | Integrated battery (20 tests) |
AA batteries | Mains electricity (power adapter) |
Standard electricity | ||
Connectivity | LumiraDx Connect cloud-based services; 2× USB ports; RFID reader; Bluetooth connectivity |
None | None | USB port; Direct RJ45 Ethernet cable; Idylla Visualizer (PDF viewer); Idylla Explore (cloud) | ||
Max. operating temperature (°C)/humidity (%) | 30/90 | 45/95 | 30/80 | 30/80 | ||
Multi-use ‡ | Yes | Yes | Yes | Yes | ||
Throughput capacity | 1 | 1 | 1 | 8 | ||
Costs (USD) | NR | Not applicable (instrument-free) |
Not applicable (instrument-free) |
NR | ||
COVID-19 Assay: Specifications |
Sample type | NS, NPS | NS | NS, NPS | NPS | |
Hands-on time (min) | 1 | 1 | <2 | <2 | ||
Running time (min) | 12 | 30 | 30 | 90 | ||
Shelf-life (months) | NR | 18 | NR | NR | ||
Costs per test (USD) | NR | >10/test | NR | NR | ||
LOD (copies/mL) | NR | 900 | 100–1112 | 500 | ||
Sensitivity (%)/Specificity (%) | 82.7/96.9 | 93.1/100.0 | 100.0/98.7 | 100.0/100.0 | ||
POC features of equipment |
Score | 39/50 (78%) | 36/50 (72%) | 36/50 (72%) | 32/50 (64%) | |
Pros |
|
|
|
|
||
Cons |
|
|
|
|
||
POC features of consumables |
Score | 9/15 (60%) | 14/15 (93%) | 7/15 (47%) | 7/15 (47%) | |
Pros |
|
|
None | None | ||
Cons |
|
None |
|
|
||
Ease of use | Score | 10/10 (100%) | 10/10 (100%) | 8/10 (80%) | 6/10 (60%) | |
Pros |
|
|
|
|
||
Cons | None | None | None |
|
||
Performance | Score | 5/15 (33%) | 7/15 (47%) | 11/15 (73%) | 11/15 (73%) | |
Pros | None |
|
|
|
||
Cons |
|
|
|
|
||
Cost | Score | 2/10 (20%) | 6/10 (60%) | 6/10 (60%) | 2/10 (20%) | |
Pros | None |
|
|
None | ||
Cons |
|
|
|
|
||
Platform versatility |
Score | 5/5 (100%) | 5/5 (100%) | 5/5 (100%) | 5/5 (100%) | |
Pros |
|
|
|
|
||
Cons | None | None | None | None |
Abbreviations: POC = point-of-care; NR = Not Reported; NS = Nasal Swab; NPS = Nasopharyngeal Sample; LoD = Limit-of-Detection. Legend: * color coding: red = overall score/category score <33.3%; orange = overall score/category score <66.6%; green = overall score/category score ≥ 66.6%; † overall score: calculated by summing the seven category scores; category scores: calculated by aggregating the scores for each variable within the respective scoring category. Please refer to Table S4 for the detailed scoring methodology; ‡ multi-use is defined as the ability to analyze multiple biomarkers from one sample on a single diagnostic device (e.g., respiratory panels).